Quality sourcing with third-party testing remains critical, especially for cagrilintide given limited vendor availability
Critical Safety Gaps for Mental Health Applications Unknown effects on cognitive function, memory, personality, mood stability beyond intended therapeutic effect Long-term impacts on brain chemistry (chronic administration effects unexplored beyond 6 weeks in animals) Potential for psychological dependence or tolerance (not studied systematically) Impacts on developing brains in adolescents and young adults (completely unknown with no pediatric studies) Drug Interactions Pose Serious Concerns BPC-157s simultaneous effects on serotonin, dopamine, GABA, glutamate, and nitric oxide systems create multiple theoretical interaction points with psychiatric medications, yet interactions are not well studied. Specific concerns include: With SSRIs and SNRIs: Risk of serotonin syndrome is genuine
BPC-157 for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption
Indications include: Medically refractory disease not responding to optimized biologic therapy Bowel obstruction from fibrostenotic stricture Intra-abdominal abscess not amenable to percutaneous drainage Complex perianal fistula (seton placement, diversion) Enterocutaneous or enterovesical fistula Dysplasia or cancer in Crohns colitis Free perforation (rare) Nutritional Therapy Exclusive enteral nutrition (EEN) effective for induction in pediatric Crohns